GlobeNewswire·Nov 10, 2026, 7:00 AM ET

Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress

Upstream Bio plans to initiate Phase 3 trials for verekitug in severe asthma & chronic rhinosinusitis with nasal polyps (CRSwNP) during Q1 2027.
The company prioritizes a development strategy aiming for best-in-class efficacy & convenient quarterly dosing across severe asthma, CRSwNP, & COPD.
Verekitug is the only known TSLP receptor antagonist currently in clinical development.
The Phase 2 VENTURE trial in COPD is ongoing with ~480 participants; enrollment completed in August 2026 with data expected in H2 2027.
The Phase 2 VALOUR LTE study in severe asthma remains active with >90% retention from the VALIANT study; data expected in H2 2027.
As of September 30, 2026, the company held $207.4 million in cash, equivalents, & short-term investments to fund operations through 2027.
R&D expenses rose to $36.6 million in Q3 2026 from $33.0 million in the prior year, driven by personnel & clinical costs.
General & administrative expenses increased to $7.2 million in Q3 2026 from $5.5 million, due to personnel costs & professional fees.
The company reported a net loss of $41.2 million for Q3 2026 compared to $33.7 million in Q3 2025.
Upcoming investor conference appearances include the Truist Securities Biopharma Symposium in November, the Evercore Healthcare Conference in late November/early December, & the Piper Sandler Healthcare Conference in early December.